Description
1 CAPSULE = 250MCG
Contains 60 Capsules
SLU-PP-332 is a synthetic agonist of estrogen-related receptors (ERRα/β/γ) that has demonstrated promising results in animal studies, particularly in mouse models of obesity and metabolic syndrome. These studies suggest that SLU-PP-332 can mimic the metabolic benefits of exercise without requiring increased physical activity or changes in food intake.PMC+4PubMed+4ResearchGate+4
Key Findings from Animal Studies1. Enhanced Fatty Acid Oxidation and Energy Expenditure
In both diet-induced obese (DIO) and ob/ob mice, SLU-PP-332 administration led to a significant increase in fatty acid oxidation and resting energy expenditure. This metabolic shift was evidenced by a lower respiratory exchange ratio (RER), indicating a preference for fat as an energy source over carbohydrates. Notably, these effects occurred without changes in food consumption or physical activity levels .PMC+1PubMed+1
2. Reduction in Fat Mass and Body Weight
Treated mice exhibited substantial reductions in fat mass and overall body weight. For instance, DIO mice experienced approximately a 12% decrease in body weight over a 28-day treatment period, despite no significant alterations in diet or activity .Technology Networks+2PMC+2PubMed+2
3. Improved Glucose Metabolism in Obese Models
While SLU-PP-332 did not significantly affect glucose metabolism in lean, chow-fed mice, it improved glucose tolerance and reduced fasting insulin levels in obese models. This suggests potential benefits for insulin sensitivity in the context of obesity .PubMed+1PMC+1PMC
4. Enhanced Muscle Function and Endurance
The compound increased oxidative muscle fibers (type IIa) and mitochondrial activity, leading to improved exercise endurance. Mice treated with SLU-PP-332 were able to run approximately 50% further than control groups, indicating enhanced muscle function .University of Florida News+3PubMed+3Fortune+3Technology Networks
5. Reduction in Liver Fat and Improved Lipid Profiles
SLU-PP-332 treatment resulted in decreased hepatic triglyceride content and reduced signs of liver steatosis. Additionally, treated mice showed lower levels of total cholesterol and triglycerides, indicating improved lipid metabolism
Legal Notice:
This product is strictly for in vitro laboratory research under controlled conditions by qualified research personnel. Not for drug, household, or other uses.
The buyer acknowledges that purchase and use of this material is subject to all
applicable UK regulations regarding research chemicals.
Keep out of reach of children.
Ensure the container is tightly sealed.
Store in a cool, dry, and shaded area, away from moisture.
Only store in the original container.
Not for Human Consumption – Research Purposes Only – Your Purchase Signifies Agreement
